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sponse is higher in these patients. Treatment effect sizes are
larger among patients who do not flare.
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Purpose: Few clinical trials have been performed in HOA. De-
spite the recent presentation of the European Ligue Against
Rheumatism recommendations, few is known with respect to the
way doctors treat symptomatic HOA patients.
Aim of this study: To describe the therapeutic uses of French
doctors in HOA according to the level of symptoms.
Methods: Prospective cross-sectional pharmacoepidemiologic
survey. A sample of 100 French rheumatologists (Rh) and 100
general practitioners (GPs) had to describe 2 HOA patients
presenting consecutively: either with a flare of symptoms, i.e.
pain score ≥ 50 mm on a VAS and functional index for hand OA
score (FIHOA [2]) ≥ 5, and or with quiescent symptoms (pain <
50 mm and FIHOA < 5). Patients were both genders, age ≥ 45
years, fulfilling the ACR criteria [1], and were initially separated
according to the level of symptoms. Data collected: Doctors
characteristics, patients demographic data and HOA description,
and treatments received. A pharmaco-economic evaluation was
also performed. Statistics: descriptive: numbers (%) and mean
(SD).
Results: 169 doctors (aged 50 years, 69% men) described 316
patients of which 178 (56%) were in the "flare" and 44% in the
non-flare group, 83% women (95% menopaused), mean age 66
years (10), mean BMI 25 (4), with a familial history of HOA in
60%. VAS Pain score rated 66 (9) mm in the flare group and
30 (11) mm in the non-flare group, and FIHOA averaged 12 (4)
and 4 (1) respectively. Treatments received: 88% in the flare
group vs 76% received level 1 or 2 analgesics (p = 0.004), 69%
vs 30% received an NSAID (p < 0.001) of whom 66 and 50%
were prescribed a gastroprotective drug respectively. 90% of the
patients in the flare group were prescribed a symptomatic slow-
acting drug in OA (SySADOA) vs 80% (p = 0.01). No difference
was observed between the groups regarding the duration of
treatments with the exception of level 1 analgesics (46 days
in the "non-flare" group vs 27; p<0.001). Topical NSAIDs were
used in 60% of patients in both groups. Steroids intra-articular
(IA) injections were performed in 16% of patients in the "flare"
group vs 4% (p < 0.001). Surprinsingly non pharmacological
therapies were more often used in "flare" patients: 38% vs 27%
(p = 0.03), and comprised physical therapy (10%), splints (22%)
and Spa therapy (6%). GPs prescribed more analgesics (93% vs
73%), more NSAIDs (62% vs 43%) and more physical therapy
(19% vs 3) than Rh. Conversely, Rh prescribed more splints
(30% vs 13), and more IA steroids (16% vs 5). Mean costs of
treatments were similar in both groups of patients (278 Euros,
patient’s perspective). Drugs accounted for 189 Euros in the
"flare" group vs 206.
Conclusions: We observed some differences between Rh and
GPs in their management of hand OA symptoms: more splints, IA
steroids injections and SySADOA prescription by RH, while GPs
use more analgesics/NSAIDs and surprisingly more physical
therapy. Further studies in this field are required to confirm our
results.
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Purpose: To determine the benefit and risk of NSAID-based pro-
phylaxis for ectopic bone formation amongst patients undergoing
total hip replacement (or revision) surgery.
Methods: A double-blind randomised placebo-controlled clini-
cal trial, stratified by treatment site and surgery (primary or
revision), was conducted in 20 orthopaedic surgery centres in
Australia and New Zealand. 902 patients undergoing elective
primary or revision total hip replacement surgery were randomly
allocated to 14 days treatment with ibuprofen (1200mg daily)
or matching placebo commenced within 24 hours of surgery.
Patients were only excluded if there was, in the opinion of the
responsible physician, a definite indication or contra-indication
for treatment with an NSAID during the 14 day study treatment
period. Outcomes were assessed 6 to 12 months after sugery
and included changes in self-reported hip pain and physical func-
tion (WOMAC), physical performance measures and radiographic
evidence of ectopic bone formation.
Results: There was only a 6% loss to follow-up for self-report
measures and a 12% loss to follow-up for radiographs. Six to
twelve months after surgery, there were no significant differences
between the ibuprofen and placebo groups for improvements in
hip pain (mean difference, 95% confidence interval: -0.1, -0.4
to 0.2, p = 0.6) or physical function (-0.1, -0.4 to 0.2, p = 0.5),
despite a much reduced risk of ectopic bone formation (relative
risk 0.69, 95% confidence interval 0.56 to 0.83) associated with
ibuprofen. There was a significantly increased risk of major
bleeding complications during the admission period (2.09, 1.00
to 4.39).
Conclusions: These data, from the largest-ever trial of prophy-
laxis against ectopic bone formation, do not support the use of
routine NSAIDs-based prophylaxis for patients undergoing total
hip replacement surgery.
A44
ASSOCIATION BETWEEN HOSPITAL AND SURGEON
VOLUME AND PATIENT REPORTED OUTCOMES
FOLLOWING REVISION TOTAL KNEE REPLACEMENT
J.N. Katz1, N.N. Mahomed2, J.W. Wright1, A.H. Fossel1,
E.A. Wright1, J.A. Baron3, J. Barrett3, E. Losina1
1Brigham and Women’s Hospital, Boston, MA, 2University of
Toronto, Toronto, ON, Canada, 3Dartmouth Medical School,
Lebanon, NH
Purpose: Over 30,000 revision total knee replacements are per-
formed annually in the US, and the number is rising steadily.
Hospital and surgeon procedure volume are associated with
perioperative mortality and complications as well as patient re-
ported functional outcomes two years following primary TKR.
The objective of this study is to determine if hospital and sur-
geon volume of TKR as associated with pain, functional status,
range of motion and satisfaction two years following revision
TKR.
Methods: We used Medicare claims to identify all patients in
four states (IL, OH, NC, TN) who had revision TKR in 2000.
We contacted these patients by mail in 2002 and invited them
to participate in a survey to assess their outcomes of revision
TKR surgery. The survey included the pain and function sub-
